Clinical Trial Update: Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer [Phase 3]

View source ↗

Summary

This Phase 3 randomized neoadjuvant trial comparing epirubicin and docetaxel with or without capecitabine in early breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• DOCETAXEL (DOCETAXEL)
• Epirubicin (epirubicin)

Snippet

Sponsor: Austrian Breast & Colorectal Cancer Study Group | Conditions: Breast Cancer | Phase 3 | Status: COMPLETED